"宣威"多结节非小细胞肺癌驱动基因突变分析OA北大核心CSTPCD

Objective:To investigate the relationship between driver gene mutations and clinicopathological features of multi-nodular non-small cell lung cancer(NSCLC),and to provide molecular diagnostic basis for the treatment of multi-nodular NSCLC patients.Methods:A total of 253 lung nodule tumor specimens from 121 patients with multiple nodules NSCLC tested at the Molecular Diagnostic Center of Yunnan Cancer Hospital between January 2018 and October 2023 were included in this study.Next-generation sequencing(NGS)or Amplification Refractory Mutation System PCR(ARMS-PCR)techniques were used to detect driver gene mutations in multi-nodular NSCLC tissues.The relationship between these mutations and clinical pathological features of patients was analyzed,in order to compare the tumor heterogeneity of lung cancer driver genes in different nodules.Results:Compared with non-"Xuanwei"NSCLC,"Xuanwei"multi-nodular NSCLC patients showed significant regional characteristics in driver gene mutations.These patients demonstrated a lower rate(20%)of epidermal growth factor receptor(EGFR)sensitive mutations(L858R,19-del),a higher rate(27.26%)of EGFR rare mutations(mainly G719/S768I,G719).The KRAS mutation rate in"Xuanwei"multi-nodular NSCLC patients(27.27%)was also significantly higher than that in non-"Xuanwei"patients(12.59%)(P<0.05).In addition,the inconsistency rate of driver gene mutations among different nodules was 69.23%in"Xuanwei"multi-nodular NSCLC patients,much higher than that in non-"Xuanwei"patients(55.07%)(P<0.05).Conclusion:"Xuanwei"multi-nodular NSCLC patients in have higher EGFR rare mutations and KRAS mutation rates,and there is higher driver gene mutation heterogeneity among different lesions in the same patient.This study will provide more options for the diagnosis and treatment strategies of"Xuanwei"multi-nodular NSCLC.